Addex Therapeutics (ADDXF) Stock Price, News & Analysis

Company Overview

Addex Therapeutics Ltd is a clinical‐stage biopharmaceutical company headquartered in Geneva, Switzerland, specializing in the discovery and development of small molecule allosteric modulators of G protein‐coupled receptors (GPCRs). The company’s research focuses primarily on metabotropic glutamate (mGlu) receptors, which play key roles in central nervous system disorders. By targeting allosteric sites on these receptors, Addex aims to achieve greater selectivity and safety compared with traditional orthosteric ligands.

The company’s lead clinical program, dipraglurant, is a negative allosteric modulator of the mGlu5 receptor being evaluated for levodopa‐induced dyskinesia in Parkinson’s disease. In parallel, Addex is advancing mGlu2 and mGlu3 receptor modulators for indications such as anxiety, depression and schizophrenia. These programs leverage the potential of allosteric modulation to fine‐tune receptor response rather than fully block or activate the receptor, which may reduce off‐target effects and improve therapeutic outcomes.

Founded in 2002 as a spin‐out from the University of Geneva, Addex has built a research and development infrastructure that spans Switzerland and the United States, with additional collaborations in Europe and North America. Over the years, the company has entered into strategic partnerships and license agreements with leading pharmaceutical firms to advance its pipeline. These collaborations have helped validate Addex’s proprietary technology and expand the reach of its investigational therapies.

Under the leadership of Chief Executive Officer Pierluigi Paracchi, Addex Therapeutics continues to leverage its expertise in GPCR allosteric modulation to address unmet medical needs in neurology and psychiatry. The company maintains a lean operating model focused on progression of its clinical candidates through key regulatory milestones, while exploring out‐licensing and co‐development opportunities to broaden the impact of its innovative drug discovery platform.

Key Stats

• Today's Range: $0.99 to $0.99
• 50-Day Range: $0.99 to $0.99
• 52-Week Range: $0.99 to $0.99
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ADDXF
• CIK: N/A
• Web: www.addextherapeutics.com
• Phone: 41 22 884 1555
• Fax: N/A
• Employees: 26
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.25